Physiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type 2 diabetes and related comorbidities (NASH, CKD and CVD), will be presenting at the 8th Aging Research Drug Discovery (ARDD), Aug. 31st – Sept. 3rd 2021, Copenhagen, Denmark.

Physiogenex to present at the 8th Aging Research and Drug Discovery (ARDD) meeting

Dr. François Briand, Director of Research and Business Development, will be presenting a poster entitled “Time-restricted feeding improves non-alcoholic steatohepatitis and liver fibrosis in diet-induced obese insulin resistant mice”. The poster session will be held on Tuesday August the 31st and September 1st from 8pm to 9pm.

If you wish to set an appointment with Dr. François Briand to discuss about your preclinical project, please contact us.

About the 8th Aging Research & Drug Discovery meeting

please visit meeting website

About Physiogenex

Physiogenex is a leading preclinical research organization providing non-clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.